Self-amplifying RNA (saRNA) Virtual Biotech seeks VC
Self-amplifying RNA (saRNA) Virtual Biotech seeks VC investment to develop a pipeline of RNA therapeutics and vaccines.
We are looking for $6-10 million for pre-series A investment.
Take a look at our prospective
+ Novel self-amplifying RNA (saRNA) Technology Platform.
+ Strong IP position on saRNA Technology Platform and Nanoparticle Delivery Vehicle.
+ This company’s Technology Platform is the “Next Generation” approach for mRNA therapeutics, cancer vaccines and infectious diseases. Multiple gene delivery, can deliver antigen or protein.
+ Superior dosing and production method by virtue of biosynthetic and self-assembling delivery system when compared to current lipid coated mRNA technology.
+ Four (4) Oncology programs are Non-Viral Gene Therapies; Technology Platform is applicable for vaccines and rare diseases too.
+ Demonstration of Technology Platform Process with Proof of Concept Studies.
+ Financing will be utilized for advancement of the oncology pipeline and continuing demonstration of process scalability.
+ This company plans to have multiple assets in the clinic by 2023.
+ Leadership Team with big pharma experience (ex-GSK). Very Strong Scientific Advisory Board. Company is based in northeastern USA.
+ Please request the CIM after Fully Executed NDA.